BridgeBio is significantly advanced its development of the new treatment for cardiac amyloidosis, leveraging Attruby. Preliminary patient data reveals potential benefits for patients affected with a severe condition. https://attr-cm794403.blog-mall.com/42988968/company-improves-attr-cm-management-with-attruby